Ocata Therapeutics Inc fka OCAT

[rocky301]

ACT/CHA Biotech...Chronological Events

PART 1: THIS IS JOINT VENTURE MATERIAL

Nov. 30 2008 ..Share Purchase Agreement

ACT purchased 4000 shares of Allied Cell Technology. 1000(25%) shares were held back until certain contingencies were met. ACT had 33% ownership which when remaining shares were transferred ACT retained a 40% ownership as they do today.

In consideration for the 4000 share investment ACT transferred employees, guaranteed lab space and lab equipment for approx. 3 years.

Parties signing this agreement: Allied Cell, signed by President Dr. Hyung-Min Chung ACT, signed by CEO William Caldwell
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-130.htm

Nov. 30, 2008..Sublicense Agreement

This License Agreement is between Allied Cell(now includes ACT) and Cha Biotech. Sublicensor is Allied Cell, Sublicensee is CHA
This sublicense agreement only gave CHA an Exclusive in South Korea
Section 2 here:
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-126.htm
Allied Cell and CHA were signing parties, Dr. Hyung-Min Chung signed both

MY summary based on these two transactions. First of all, I am pretty sure the Exclusive License Agreement between ACT and Allied is missing from public view which for me at least causes most of the confusion. Based on what I can see, SCRMI(the partnership) holds the worldwide exclusive license and CHA received an Exclusive License for South Korea only back in 2008.


PART 2: THIS SECTION APPLIES TO ACT/CHA DEALS...(not part of joint venture)

NOTE: Both Agreements below are for South Korea ONLY. Both agreements allow CHA non-exclusive worldwide rights to sublicense technology for RESEARCH ONLY..NOT FOR THE SALE

March 30, 2009...Exclusive License Agreement with CHA and ACTC RPE Technology
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-128.htm

MAY 8, 2009...
Exclusive License Agreement Cha and ACTC's Single Cell Biopsy Technique
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-129.htm

PART 3: THIS SECTION APPLIES TO NEWS TODAY

July 21, 2011...ACT Obtains Exclusive License For Hemangioblast Technology In North America
ACT to Aggressively Pursue Clinical Translation of "Universal" Blood, Platelets and Off-the-Shelf Mesenchymal Stem Cells Derived From Embryonic Stem Cells, Among Other Technologies

Under the terms of the agreement, SCRMI exclusively licenses the rights to its hemangioblast program to ACT for North America (United States and Canada) and to CHA Biotech for Korea and Japan.

The ownership in SCMRI remains largely unchanged between ACT and CHA Biotech, with the joint venture ceasing internal research activity and transitioning to a licensing entity.